Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Holdings Raised by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. increased its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 64.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,599 shares of the specialty pharmaceutical company’s stock after purchasing an additional 4,140 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Supernus Pharmaceuticals were worth $330,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. GAMMA Investing LLC lifted its position in shares of Supernus Pharmaceuticals by 97.1% in the 3rd quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company’s stock worth $25,000 after buying an additional 398 shares during the last quarter. Fidelis Capital Partners LLC acquired a new stake in Supernus Pharmaceuticals during the first quarter worth about $33,000. EntryPoint Capital LLC bought a new position in Supernus Pharmaceuticals in the first quarter worth about $43,000. Meeder Asset Management Inc. acquired a new position in Supernus Pharmaceuticals in the second quarter valued at approximately $47,000. Finally, Innealta Capital LLC acquired a new position in Supernus Pharmaceuticals in the second quarter valued at approximately $51,000.

Analysts Set New Price Targets

Several brokerages recently issued reports on SUPN. Piper Sandler reissued a “neutral” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Cowen reiterated a “buy” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. Finally, StockNews.com upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th.

Supernus Pharmaceuticals Trading Up 1.4 %

SUPN opened at $34.87 on Thursday. Supernus Pharmaceuticals, Inc. has a twelve month low of $23.05 and a twelve month high of $35.56. The stock has a market cap of $1.92 billion, a PE ratio of -120.24 and a beta of 0.88. The business’s 50 day moving average is $33.05 and its 200-day moving average is $30.39.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $0.36 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.39 by ($0.03). The business had revenue of $168.30 million for the quarter, compared to analyst estimates of $148.83 million. Supernus Pharmaceuticals had a return on equity of 0.56% and a net margin of 0.83%. The company’s revenue was up 24.1% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.02) EPS. As a group, analysts forecast that Supernus Pharmaceuticals, Inc. will post 1.53 EPS for the current year.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.